Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9696685 | 0.93 | TSHR (0.55) | TSHRNPC1RAB9ACTSKCTSL | |
| Potassium Ion SCHEMBL28727524 | 0.85 | TSHR (0.47) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL4965733 | 0.84 | TSHR (0.53) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL22474284 | 0.82 | TSHR (0.51) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL29242751 | 0.82 | TSHR (0.51) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL9831570 | 0.82 | TSHR (0.51) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL10658684 | 0.81 | NPC1 (0.55) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL16521417 | 0.81 | TDP1 (0.50) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL6826673 | 0.81 | TSHR (0.53) | TSHRNPC1RAB9ACTSKCTSL | |
| SCHEMBL1838248 | 0.81 | SLC6A2 (0.54) | TSHRNPC1RAB9ACTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101027092-A | Non-absorbent and absorbent articles for inhibiting the production of exoproteins | KIMBERLY CLARK CO (US) | 2007-08-29 | — | — | CN | claimed |
| CN-105980345-B | Method for continuously producing ketomalonic acid compound using flow reactor | 组合化学工业株式会社 | 2019-12-20 | — | — | CN | disclosed |
| CN-104837637-B | Fabric for digital printing pre-processes object | 路博润先进材料公司 | 2018-09-25 | — | — | CN | disclosed |
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| CN-102656172-B | 8-oxodihydropurine derivatives | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2016-03-23 | — | — | CN | disclosed |
| CN-104837637-A | Fabric pretreatment for digital printing | LUBRIZOL ADVANCED MAT INC | 2015-08-12 | — | — | CN | disclosed |
| CN-101967146-B | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC | 2015-04-08 | — | — | CN | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| CN-101610764-B | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LTD | 2012-11-21 | — | — | CN | disclosed |
| CN-102656172-A | 8-oxodihydropurine derivatives | DAINIPPON SUMITOMO PHARMA CO | 2012-09-05 | — | — | CN | disclosed |
| CN-101967146-A | Ep4 receptor inhibitors to treat rheumatoid arthritis | PRIZER JAPAN INC | 2011-02-09 | — | — | CN | disclosed |
| CN-101610764-A | As EP 4The heterocyclic carbamate derivatives of receptor stimulating agent | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| CN-101027092-A | Non-absorbent and absorbent articles for inhibiting the production of exoproteins | KIMBERLY CLARK CO (US) | 2007-08-29 | — | — | CN | disclosed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| CN-1477960-A | EPA receptor inhibitors to treat rheumatoid arthritis | — | 2004-02-25 | — | — | CN | disclosed |
| CN-1476448-A | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ������ҩ������˾ | 2004-02-18 | — | — | CN | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
| EP-0489933-A1 | BILE ALCOHOL AND DRUG CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA CO., LTD. (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | TSHR 1037/4885NPC1 791/4885RAB9A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.